Squarepoint’s Accelerate Diagnostics AXDX Stock Holding History

Squarepoint’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,147	Closed	-$22K	–	3553
2023 Q1	$22K	Buy	+3,147	New	+$18.9K	﹤0.01%	3126
2022 Q1	–	Sell	-1,114	Closed	-$58K	–	2812
2021 Q4	$58K	Buy	+1,114	New	+$62K	﹤0.01%	3006
2021 Q1	–	Sell	-3,374	Closed	-$256K	–	3101
2020 Q4	$256K	Buy	+3,374	New	+$302K	﹤0.01%	2334
2020 Q3	–	Sell	-1,802	Closed	-$273K	–	2482
2020 Q2	$273K	Buy	+1,802	New	+$178K	﹤0.01%	1653
2019 Q2	–	Sell	-2,675	Closed	-$562K	–	2363
2019 Q1	$562K	Buy	+2,675	New	+$502K	0.01%	1424
2018 Q4	–	Sell	-1,174	Closed	-$269K	–	1923
2018 Q3	$269K	Buy	+1,174	New	+$260K	﹤0.01%	1595
2018 Q1	–	Sell	-2,462	Closed	-$645K	–	1685
2017 Q4	$645K	Buy	+2,462	New	+$577K	0.01%	1054
2017 Q3	–	Sell	-987	Closed	-$270K	–	1608
2017 Q2	$270K	Buy	+987	New	+$268K	0.01%	1176
2017 Q1	–	Sell	-1,224	Closed	-$254K	–	1521
2016 Q4	$254K	Buy	+1,224	New	+$291K	0.01%	1258

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Squarepoint's AXDX Position: Q2 2023 in Review

Squarepoint sold out of Accelerate Diagnostics (AXDX) in Q2 2023, closing a stake of 3,147 shares — an estimated $22K sold.

Squarepoint first reported a position in AXDX in Q4 2016 and held it in 9 quarters. The position peaked at $645K in Q4 2017. 51 funds tracked by Wall St. Rank hold AXDX as of Q2 2023.

Squarepoint reported no remaining Accelerate Diagnostics position as of Q2 2023 after selling out during the quarter.
Squarepoint sold 3,147 Accelerate Diagnostics shares in Q2 2023, an estimated $22K.
Squarepoint first reported a position in Accelerate Diagnostics in Q4 2016 and held it in 9 quarters.
Squarepoint's Accelerate Diagnostics position peaked at $645K in Q4 2017.
51 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2023.

Based on Squarepoint's 13F filing for Q2 2023, filed 14 Aug 2023.